EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, ChemoCentryx's enterprise value is $3,482.49 Mil.
ChemoCentryx's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 was $-126.54 Mil. Therefore, ChemoCentryx's EV-to-EBITDA for today is -27.52.
The historical rank and industry rank for ChemoCentryx's EV-to-EBITDA or its related term are showing as below:
CCXI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -150.04 Med: -7.25 Max: 36.48
Current: -27.52
During the past 13 years, the highest EV-to-EBITDA of ChemoCentryx was 36.48. The lowest was -150.04. And the median was -7.25.
CCXI's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.49
vs CCXI: -27.52
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
ChemoCentryx EV-to-EBITDA Historical Data
The historical data trend for ChemoCentryx's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ChemoCentryx's EV-to-EBITDA
For the Biotechnology subindustry, ChemoCentryx's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ChemoCentryx's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ChemoCentryx's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ChemoCentryx's EV-to-EBITDA falls into.
ChemoCentryx EV-to-EBITDA Calculation
ChemoCentryx's EV-to-EBITDA for today is calculated as:
ChemoCentryx's current Enterprise Value is $3,482.49 Mil.
ChemoCentryx's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-126.54 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ChemoCentryx (NAS:CCXI) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
ChemoCentryx's PE Ratio for today is calculated as:
ChemoCentryx's share price for today is $51.99.
ChemoCentryx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.890.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of ChemoCentryx's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
ChemoCentryx Inc is a biopharmaceutical company involved in the discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are an antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CCXI has been successfully added to your 